However the NHS spending watchdog has announced Mounjaro will only be given to 220,000 people in England during the first three years - despite 3.4 million people being eligible for it. Trials have ...

However, Dr Kath McCullough, NHS England’s national speciality adviser for obesity, warned that weight loss jabs “are not a ...

Jim Gaffigan revealed he lost 50 pounds via a weight loss drug after struggling for years with his weight. Photos show the ...

Lilly said patients taking Zepbound lost about 20% of their weight on average compared with nearly 14% for Wegovy. The drug ...

The rise of weight loss drugs is not only changing individual lives, but also reshaping large sections of the economy.

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...

Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy. The drugmaker also said more patients taking Zepbound achieved at least 25% weight loss ...

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...